![\"Krefting](\"http:\/\/ajnrdigest.org\/wp-content\/uploads\/2020\/08\/Krefting-pic.jpg\")
<\/a>Ira Krefting<\/p><\/div>\n
This study was initiated following the 2009 FDA Advisory Committee on Nephrogenic Systemic Fibrosis and the subsequent safety labeling changes contraindicating gadodiamide (Omniscan), gadopentetate (Magnevist), and gadoversetamide (Optimark) in patients with severe renal failure (estimated glomerular filtration rate [eGFR] < 30). Gadobenate (MultiHance), structurally related to gadopentetate, was not uniquely associated with nephrogenic systemic fibrosis (NSF) reports and was not contraindicated. However, gadobenate was approved in 2004 and therefore lacked the longer market exposure of the contraindicated gadolinium-based contrast agents (GBCAs). The study was performed to further evaluate the NSF risk with gadobenate. When gadolinium retention was recognized as a potential safety issue, measuring gadolinium in the skin was added to the protocol.<\/p>\n","protected":false},"excerpt":{"rendered":"
… more »<\/a><\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","enabled":false},"version":2}},"categories":[111],"tags":[5],"jetpack_publicize_connections":[],"yoast_head":"\nNephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration - AJNR News Digest<\/title>\n<meta name=\"description\" content=\"Dr. Krefting discusses Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration for the September-October 2020 AJNR News Digest.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration - AJNR News Digest\" \/>\n<meta property=\"og:description\" content=\"Dr. Krefting discusses Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration for the September-October 2020 AJNR News Digest.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/\" \/>\n<meta property=\"og:site_name\" content=\"AJNR News Digest\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-31T18:08:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-08-31T21:28:47+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/ajnrdigest.org\/wp-content\/uploads\/2020\/08\/Krefting-pic.jpg\" \/>\n<meta name=\"author\" content=\"Laura Wilhelm\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Laura Wilhelm\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/\",\"url\":\"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/\",\"name\":\"Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration - AJNR News Digest\",\"isPartOf\":{\"@id\":\"https:\/\/ajnrdigest.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/ajnrdigest.org\/wp-content\/uploads\/2020\/08\/Krefting-pic.jpg\",\"datePublished\":\"2020-08-31T18:08:10+00:00\",\"dateModified\":\"2020-08-31T21:28:47+00:00\",\"author\":{\"@id\":\"https:\/\/ajnrdigest.org\/#\/schema\/person\/c3641145fed927716a0613a3baf41484\"},\"description\":\"Dr. Krefting discusses Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration for the September-October 2020 AJNR News Digest.\",\"breadcrumb\":{\"@id\":\"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/#primaryimage\",\"url\":\"http:\/\/ajnrdigest.org\/wp-content\/uploads\/2020\/08\/Krefting-pic.jpg\",\"contentUrl\":\"http:\/\/ajnrdigest.org\/wp-content\/uploads\/2020\/08\/Krefting-pic.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ajnrdigest.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"September-October 2020\",\"item\":\"https:\/\/ajnrdigest.org\/category\/202009\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ajnrdigest.org\/#website\",\"url\":\"https:\/\/ajnrdigest.org\/\",\"name\":\"AJNR News Digest\",\"description\":\"The Latest Insights and Technology in Neuroimaging\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ajnrdigest.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ajnrdigest.org\/#\/schema\/person\/c3641145fed927716a0613a3baf41484\",\"name\":\"Laura Wilhelm\",\"url\":\"https:\/\/ajnrdigest.org\/author\/lwilhelm\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration - AJNR News Digest","description":"Dr. Krefting discusses Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration for the September-October 2020 AJNR News Digest.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/","og_locale":"en_US","og_type":"article","og_title":"Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration - AJNR News Digest","og_description":"Dr. Krefting discusses Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration for the September-October 2020 AJNR News Digest.","og_url":"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/","og_site_name":"AJNR News Digest","article_published_time":"2020-08-31T18:08:10+00:00","article_modified_time":"2020-08-31T21:28:47+00:00","og_image":[{"url":"http:\/\/ajnrdigest.org\/wp-content\/uploads\/2020\/08\/Krefting-pic.jpg"}],"author":"Laura Wilhelm","twitter_misc":{"Written by":"Laura Wilhelm","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/","url":"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/","name":"Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration - AJNR News Digest","isPartOf":{"@id":"https:\/\/ajnrdigest.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/#primaryimage"},"image":{"@id":"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/#primaryimage"},"thumbnailUrl":"http:\/\/ajnrdigest.org\/wp-content\/uploads\/2020\/08\/Krefting-pic.jpg","datePublished":"2020-08-31T18:08:10+00:00","dateModified":"2020-08-31T21:28:47+00:00","author":{"@id":"https:\/\/ajnrdigest.org\/#\/schema\/person\/c3641145fed927716a0613a3baf41484"},"description":"Dr. Krefting discusses Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration for the September-October 2020 AJNR News Digest.","breadcrumb":{"@id":"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/#primaryimage","url":"http:\/\/ajnrdigest.org\/wp-content\/uploads\/2020\/08\/Krefting-pic.jpg","contentUrl":"http:\/\/ajnrdigest.org\/wp-content\/uploads\/2020\/08\/Krefting-pic.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/ajnrdigest.org\/nephrogenic-systemic-fibrosis-risk-assessment-and-skin-biopsy-quantification-in-patients-with-renal-disease-following-gadobenate-contrast-administration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ajnrdigest.org\/"},{"@type":"ListItem","position":2,"name":"September-October 2020","item":"https:\/\/ajnrdigest.org\/category\/202009\/"},{"@type":"ListItem","position":3,"name":"Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration"}]},{"@type":"WebSite","@id":"https:\/\/ajnrdigest.org\/#website","url":"https:\/\/ajnrdigest.org\/","name":"AJNR News Digest","description":"The Latest Insights and Technology in Neuroimaging","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ajnrdigest.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ajnrdigest.org\/#\/schema\/person\/c3641145fed927716a0613a3baf41484","name":"Laura Wilhelm","url":"https:\/\/ajnrdigest.org\/author\/lwilhelm\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p2Mro2-1sX","_links":{"self":[{"href":"https:\/\/ajnrdigest.org\/wp-json\/wp\/v2\/posts\/5639"}],"collection":[{"href":"https:\/\/ajnrdigest.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ajnrdigest.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ajnrdigest.org\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/ajnrdigest.org\/wp-json\/wp\/v2\/comments?post=5639"}],"version-history":[{"count":4,"href":"https:\/\/ajnrdigest.org\/wp-json\/wp\/v2\/posts\/5639\/revisions"}],"predecessor-version":[{"id":5663,"href":"https:\/\/ajnrdigest.org\/wp-json\/wp\/v2\/posts\/5639\/revisions\/5663"}],"wp:attachment":[{"href":"https:\/\/ajnrdigest.org\/wp-json\/wp\/v2\/media?parent=5639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ajnrdigest.org\/wp-json\/wp\/v2\/categories?post=5639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ajnrdigest.org\/wp-json\/wp\/v2\/tags?post=5639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}